TNGX
Tango Therapeutics Inc.
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Revenue | 62.4M | 42.1M | 36.5M | 24.9M | 37.0M | 7.7M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Expenses | ||||||
| R&D Expenses | — | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — | — |
| Total Op. Expenses | — | — | — | — | — | — |
| Operating Income | -111.3M | -145.6M | -114.2M | -111.1M | -58.2M | -52.2M |
| EBITDA | — | — | — | — | — | — |
| Below the Line | ||||||
| Interest Expense | — | — | — | — | — | — |
| Pre-Tax Income | — | — | — | — | — | — |
| Income Tax | — | — | — | — | — | — |
| Net Income | -101.6M | -130.3M | -101.7M | -108.2M | -58.2M | -52.0M |
| Per Share | ||||||
| EPS (basic) | — | — | — | — | — | — |
| EPS (diluted) | — | — | — | — | — | — |
| Shares | ||||||
| Basic Shares | — | — | — | — | — | — |
| Diluted Shares | 116M | 109M | 95M | 88M | 62M | 40M |